These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24074052)

  • 61. The muscarinic M(4) receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [(35)S] GTPγS binding.
    Chapman KL; Vaswani D; Hendry N; Langmead CJ; Kew JN; Watson JM
    Eur J Pharmacol; 2011 Feb; 652(1-3):1-6. PubMed ID: 21114972
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae.
    Stewart GD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Aug; 78(2):205-14. PubMed ID: 20466821
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M
    Dallagnol JCC; Khajehali E; van der Westhuizen ET; Jörg M; Valant C; Gonçalves AG; Capuano B; Christopoulos A; Scammells PJ
    J Med Chem; 2018 Apr; 61(7):2875-2894. PubMed ID: 29544056
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.
    Mistry R; Dowling MR; Challiss RA
    Br J Pharmacol; 2005 Feb; 144(4):566-75. PubMed ID: 15655507
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.
    Abdul-Ridha A; Lane JR; Mistry SN; López L; Sexton PM; Scammells PJ; Christopoulos A; Canals M
    J Biol Chem; 2014 Nov; 289(48):33701-11. PubMed ID: 25326383
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Allosteric modulators of M
    Widman CJ; Ventresca S; Dietrich J; Elmslie G; Smith H; Kaup G; Wesley A; Doenecke M; Williams FE; Schiefer IT; Ellis J; Messer WS
    Sci Rep; 2024 Jun; 14(1):14901. PubMed ID: 38942828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors.
    Lanzafame A; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Muscarinic receptor M
    Dall C; Weikop P; Dencker D; Molander AC; Wörtwein G; Conn PJ; Fink-Jensen A; Thomsen M
    Drug Alcohol Depend; 2017 Jul; 176():154-161. PubMed ID: 28544993
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.
    Salovich JM; Vinson PN; Sheffler DJ; Lamsal A; Utley TJ; Blobaum AL; Bridges TM; Le U; Jones CK; Wood MR; Daniels JS; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5084-8. PubMed ID: 22738637
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors.
    Jakubík J; Bacáková L; el-Fakahany EE; Tucek S
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1077-83. PubMed ID: 7562472
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor.
    Romagnoli R; Baraldi PG; Carrion MD; Cara CL; Cruz-Lopez O; Iaconinoto MA; Preti D; Shryock JC; Moorman AR; Vincenzi F; Varani K; Andrea Borea P
    J Med Chem; 2008 Sep; 51(18):5875-9. PubMed ID: 18729349
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor.
    Mistry SN; Lim H; Jörg M; Capuano B; Christopoulos A; Lane JR; Scammells PJ
    ACS Chem Neurosci; 2016 May; 7(5):647-61. PubMed ID: 26891194
    [TBL] [Abstract][Full Text] [Related]  

  • 76. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
    Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The pharmacologic characterization of allosteric molecules: Gq protein activation.
    Bdioui S; Verdi J; Pierre N; Trinquet E; Roux T; Kenakin T
    J Recept Signal Transduct Res; 2019 Apr; 39(2):106-113. PubMed ID: 31322035
    [No Abstract]   [Full Text] [Related]  

  • 78. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 79. M2, M3, and M4 muscarinic receptors are expressed in the guinea pig gallbladder.
    Cabadak H; Cuadra AE; El-Fakahany EE; Kan B
    J Recept Signal Transduct Res; 2009; 29(1):63-6. PubMed ID: 19519171
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.